Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

High response rate found for temozolomide plus celecoxib in recurrent malignant glioma

Dec. 9, 2002

Allos to begin rolling NDA submission for RSR-13

Dec. 5, 2002

Swissmedic approves Glivec for first-line treatment of CML

Dec. 5, 2002

Preclinical efficacy of Cerebragel in brain cancer

Dec. 5, 2002

Sankyo scientists prepare benzopyran compounds with multiple mechanisms of action

Dec. 5, 2002

T-138067 inactive in astrocytoma and glioblastoma multiforme

Dec. 5, 2002

Tolerability of intratumoral DTI-015 in recurrent malignant glioma

Dec. 5, 2002

Enzyme-inducing anticonvulsants improve tolerability of CCI-779 in patients with CNS tumors

Dec. 5, 2002

Improved tolerability of PZA in glioblastoma multiforme patients receiving anticonvulsants

Dec. 5, 2002

EMD-121794 reported to be well tolerated in patients with malignant gliomas

Dec. 5, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...